Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa–Dependent Manner
Background & Aims
Patients with chronic hepatitis C virus (HCV) infection display great variability in disease activity and progression. Although virus-specific adaptive immune responses have been characterized extensively and found to be impaired in chronic hepatitis C, the role of innate immune responses in disease activity and progression of chronic hepatitis C is not well understood.
Methods
We studied 42 HCV-infected patients and 12 healthy uninfected controls.
Results
We found an increased frequency of natural killer (NK) cells expressing tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), NKp44, NKG2C, and CD122 in chronic hepatitis C as compared with healthy controls (P < .05 for all markers) and stronger activation of NK cells in the liver than in the blood (P < .05). This NK cell phenotype was associated with polarization of NK cell function toward CD107a expression as a marker of degranulation, but with not increased interferon (IFN)-γ production of CD56dim NK cells. The polarized NK cell phenotype correlated with alanine aminotransferase levels (r2 = 0.312, P = .03). To investigate whether in vivo exposure of NK cells to HCV-induced type I IFN was causing this NK cell phenotype, peripheral blood mononuclear cells from 10 healthy controls and 8 HCV-infected patients were stimulated in the presence of IFN-alfa, which resulted in increased NK cell expression of TRAIL and CD107a (P < .001), but not IFN-γ.
Conclusions
Collectively, these results describe a polarized NK cell phenotype induced by chronic exposure to HCV-induced IFN-alfa. This phenotype may contribute to liver injury through TRAIL expression and cytotoxicity, whereas the lacking increase in IFN-γ production may facilitate the inability to clear HCV.
Abbreviations used in this paper: IFN, interferon, IL, interleukin, IQR, interquartile range, KIR, killer cell immunoglobulin-like receptor, NK, natural killer, PBMCs, peripheral blood mononuclear cells, TRAIL, tumor necrosis factor–related apoptosis-inducing ligand
To access this article, please choose from the options below
Conflicts of interest The authors disclose no conflicts.
Funding This study was supported by the intramural research program of the National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health; and Golo Ahlenstiel is the recipient of grant AH173/1-1 from the Deutsche Forschungsgemein-Schaft, Bonn, Germany.
PII: S0016-5085(09)01559-5
doi:10.1053/j.gastro.2009.08.066
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

